Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081452 | 0.77 | NPC1 (0.36) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL782929 | 0.72 | LMNA (0.37) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL15348173 | 0.69 | POLB (0.33) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL20889885 | 0.69 | LMNA (0.35) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL10883829 | 0.69 | LMNA (0.35) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL21964686 | 0.68 | USP1 (0.33) | — | |
| SCHEMBL14856633 | 0.67 | TSHR (0.41) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL21961581 | 0.67 | MEN1 (0.35) | NPC1LMNARAB9A | |
| SCHEMBL2697746 | 0.66 | CYP2B6 (0.41) | NPC1MITFLMNATP53RAB9A | |
| SCHEMBL22792122 | 0.64 | NPC1 (0.33) | NPC1MITFLMNATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NPC1 4595/4885MITF 685/4885LMNA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.